| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/25/2001 | CA2391651A1 Protein c derivatives |
| 05/25/2001 | CA2391531A1 Placental human neurokinin b precursor |
| 05/25/2001 | CA2391530A1 Tr3-specific binding agents and methods for their use |
| 05/25/2001 | CA2391502A1 Aplidine treatment of cancers |
| 05/25/2001 | CA2391212A1 Methods and compositions for identifying disease markers |
| 05/25/2001 | CA2391032A1 Personal care articles comprising cationic polymer coacervate compositions |
| 05/25/2001 | CA2390607A1 Materials and methods for detection and treatment of breast cancer |
| 05/25/2001 | CA2390431A1 Treatment of subnormal bone mineral density |
| 05/25/2001 | CA2390071A1 Aza compounds having neuronal activity |
| 05/25/2001 | CA2390051A1 Thymidylate synthase polymorphism for predicting chemotherapeutic response |
| 05/25/2001 | CA2390031A1 Double-stranded rna receptor (dsrna-r) and methods relating thereto |
| 05/25/2001 | CA2389289A1 Mammalian toxicological response markers |
| 05/25/2001 | CA2388844A1 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | CA2388807A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2388705A1 Treatment of sle with dehydroepiandrosterone |
| 05/25/2001 | CA2386579A1 Neurophilin ligands for treating ocular conditions |
| 05/25/2001 | CA2380532A1 Use of h1 antagonist and a safe steroid to treat eye conditions |
| 05/24/2001 | US20010001791 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| 05/24/2001 | US20010001669 Compound delivery using rapidly dissolving collagen film |
| 05/23/2001 | EP1101493A2 New combination of formoterol and budesonide |
| 05/23/2001 | EP1101112A2 Leptin-mediated gene-induction |
| 05/23/2001 | EP1100967A2 DUPLICATIONS OF HUMAN CHROMOSOME 15q24-25 AND ANXIETY DISORDERS, DIAGNOSTIC METHODS FOR THEIR DETECTION |
| 05/23/2001 | EP1100964A1 Gene sequence variances with utility in determining the treatment of disease |
| 05/23/2001 | EP1100963A2 Human ccr-2 gene polymorphisms |
| 05/23/2001 | EP1100962A1 Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases |
| 05/23/2001 | EP1100961A1 Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases |
| 05/23/2001 | EP1100921A2 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 05/23/2001 | EP1100913A1 Mekk1 serine threonine kinases -interacting fha forkhead associated domain protein 1 (mif1) |
| 05/23/2001 | EP1100910A1 Dna encoding a human inhibitor-of-apoptosis protein; hiap3 |
| 05/23/2001 | EP1100909A2 Dna replication- and repair-associated proteins |
| 05/23/2001 | EP1100908A2 Human receptor-associated proteins |
| 05/23/2001 | EP1100907A2 Human cytoskeletal proteins |
| 05/23/2001 | EP1100906A1 Kdel receptor inhibitors |
| 05/23/2001 | EP1100896A1 Dna encoding snorf33 receptor |
| 05/23/2001 | EP1100895A2 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 05/23/2001 | EP1100887A1 Growth differentiation factor-11 |
| 05/23/2001 | EP1100882A1 Human protein kinase h2lau20 |
| 05/23/2001 | EP1100826A1 Isoforms of human calcium sensing receptor |
| 05/23/2001 | EP1100822A1 Secreted cysteine rich protein-6 (scrp-6) |
| 05/23/2001 | EP1100817A1 Endogenous retrovirus tumor associated nucleic acids and antigens |
| 05/23/2001 | EP1100813A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb |
| 05/23/2001 | EP1100803A2 Pyrrolo 2,1-b] 1,3]benzothiazepines with atypical antipsychotic activity |
| 05/23/2001 | EP1100787A1 Lipid-lowering quinazoline derivative |
| 05/23/2001 | EP1100781A1 High affinity ligands for nociceptin receptor orl-1 |
| 05/23/2001 | EP1100771A1 Compounds and compositions for delivering active agents |
| 05/23/2001 | EP1100589A2 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| 05/23/2001 | EP1100547A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 05/23/2001 | EP1100543A2 Conjugates targeted to the interleukin-2 receptors |
| 05/23/2001 | EP1100541A1 Hydrogel for the therapeutic treatment of aneurysms |
| 05/23/2001 | EP1100533A2 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
| 05/23/2001 | EP1100530A1 Use of glp-1 and analogues for preventing type ii diabetes |
| 05/23/2001 | EP1100528A2 Use of novel agents inducing cell death in synergy with interferons |
| 05/23/2001 | EP1100525A2 Modulation of apoptosis |
| 05/23/2001 | EP1100522A1 Pulmonary delivery of active agents |
| 05/23/2001 | EP1100521A1 C7f2-a novel potassium channel beta-subunit |
| 05/23/2001 | EP1100519A1 Multibinding agents that modulate nmda receptors |
| 05/23/2001 | EP1100510A2 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism |
| 05/23/2001 | EP1100507A1 Antioxidant composition and method of treating diseases using same |
| 05/23/2001 | EP1100506A1 Integrin receptor antagonists |
| 05/23/2001 | EP1100504A2 Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| 05/23/2001 | EP1100499A1 Prevention of migraine recurrence |
| 05/23/2001 | EP1100491A1 Ophthalmic compositions for treating ocular hypertension |
| 05/23/2001 | EP1100480A2 Cholinergic agents in the treatment of presbyopia |
| 05/23/2001 | EP1100473A2 Absorbable brachytherapy and chemotherapy delivery devices and methods |
| 05/23/2001 | EP1100469A1 Rapidly disintegrable solid preparation |
| 05/23/2001 | EP1100468A1 Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| 05/23/2001 | EP1100454A1 Pharmaceutical compositions and methods for managing skin conditions |
| 05/23/2001 | EP1100433A1 Finely dispersed emulsifier-free systems of the oil-in-water and water-in-oil type, containing boron nitride |
| 05/23/2001 | EP1100431A1 Finely dispersed emulsifier-free systems of the oil-in-water and water-in-oil type |
| 05/23/2001 | DE19943786A1 Antiviral agent, e.g. vaccine, antibody, agent that inhibits viral replication, transcription or translation, useful for preventing or treating tumors (or conditions which may become tumorous) associated with viral infections |
| 05/23/2001 | CN1296529A Method for screening therapeutic agents |
| 05/23/2001 | CN1296413A Composition and method for modulating cytokine release in response to genotoxic agents |
| 05/23/2001 | CN1296410A Methods for inhibiting MRP1 |
| 05/23/2001 | CN1296408A Methods for inhibiting MRP1 |
| 05/23/2001 | CN1296011A Purine L-nucleoside, its analogue and use thereof |
| 05/22/2001 | US6236946 Nuclear receptor ligands and ligand binding domains |
| 05/22/2001 | US6235891 Glucocorticoid receptor agonist and decreased PP5 |
| 05/22/2001 | US6235879 Apoptosis modulators that interact with the Huntington's disease gene |
| 05/22/2001 | US6235782 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 05/22/2001 | US6235776 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| 05/22/2001 | US6235773 Administering skin thickening agent |
| 05/22/2001 | US6235771 Anilide derivative, production and use thereof |
| 05/22/2001 | US6235764 Isothiazole derivatives useful as anticancer agents |
| 05/22/2001 | US6235754 Using 1,4-diaryl-(2-fluoro- or 2,3-difluoro-)-2-butene |
| 05/22/2001 | US6235745 Use of 5HT3, antagonists for promoting intestinal lavage |
| 05/22/2001 | US6235725 Methods and compositions for the prevention of tolerance to medications |
| 05/22/2001 | US6235722 Pharmacological preparation |
| 05/22/2001 | US6235713 Vascular endothelial growth factor-D (VEGF-D) polypeptides |
| 05/22/2001 | US6235706 Combination therapy for reducing the risks associated with cardiovascular disease |
| 05/22/2001 | US6235311 Pharmaceutical composition containing a combination of a statin and aspirin and method |
| 05/22/2001 | US6235291 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained |
| 05/22/2001 | US6235285 An isolated polypeptide comprising a heterologous amino acid sequence fused to specific polynucleotide sequence |
| 05/17/2001 | WO2001035102A2 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | WO2001034833A2 Regulating endogenous inhibitor at atp synthase |
| 05/17/2001 | WO2001034805A2 Human vanilloid receptor gene |
| 05/17/2001 | WO2001034799A1 6 human secreted proteins |
| 05/17/2001 | WO2001034651A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 05/17/2001 | WO2001034640A2 Peptide (virip) which inhibits a circulating virus in humans and the use thereof |
| 05/17/2001 | WO2001034623A1 29 human secreted proteins |
| 05/17/2001 | WO2001034614A2 Compositions and methods for double-targeting virus infections and targeting cancer cells |